Marrone Bio Innovations (NASDAQ:MBII) Downgraded by StockNews.com

StockNews.com cut shares of Marrone Bio Innovations (NASDAQ:MBIIGet Rating) from a hold rating to a sell rating in a research report released on Friday morning.

Several other equities research analysts have also commented on MBII. Zacks Investment Research raised shares of Marrone Bio Innovations from a sell rating to a hold rating in a report on Friday, March 18th. Canaccord Genuity Group lowered shares of Marrone Bio Innovations from a buy rating to a hold rating and lowered their price target for the company from $2.00 to $1.30 in a report on Friday, March 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Marrone Bio Innovations presently has a consensus rating of Hold and an average price target of $2.01.

NASDAQ:MBII opened at $0.97 on Friday. Marrone Bio Innovations has a one year low of $0.55 and a one year high of $1.95. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average is $0.97 and its two-hundred day moving average is $0.81.

Marrone Bio Innovations (NASDAQ:MBIIGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The basic materials company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Marrone Bio Innovations had a negative net margin of 47.07% and a negative return on equity of 65.95%. During the same quarter in the previous year, the business earned ($0.02) earnings per share. Research analysts forecast that Marrone Bio Innovations will post -0.05 earnings per share for the current fiscal year.

In related news, Director Pamela G. Marrone sold 22,728 shares of the company’s stock in a transaction dated Thursday, March 24th. The shares were sold at an average price of $1.11, for a total transaction of $25,228.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in Marrone Bio Innovations during the 3rd quarter valued at about $31,000. Allspring Global Investments Holdings LLC purchased a new stake in Marrone Bio Innovations during the 1st quarter valued at about $43,000. Philadelphia Trust Co. purchased a new stake in Marrone Bio Innovations during the 4th quarter valued at about $39,000. Wells Fargo & Company MN grew its stake in Marrone Bio Innovations by 676.8% during the 4th quarter. Wells Fargo & Company MN now owns 60,982 shares of the basic materials company’s stock valued at $44,000 after acquiring an additional 53,132 shares in the last quarter. Finally, Clear Harbor Asset Management LLC grew its stake in Marrone Bio Innovations by 41.1% during the 4th quarter. Clear Harbor Asset Management LLC now owns 75,677 shares of the basic materials company’s stock valued at $55,000 after acquiring an additional 22,027 shares in the last quarter. Hedge funds and other institutional investors own 68.42% of the company’s stock.

About Marrone Bio Innovations (Get Rating)

Marrone Bio Innovations, Inc discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects.

See Also

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.